|
|
Article: Ista Licenses Senju Drugs, Expands Glaucoma Lineup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Adding to its portfolio of eye disease therapeutics, Ista Pharmaceuticals licensed a calcium channel blocker and a prostaglandin from Senju Pharmaceuticals Co. Ltd.
The Irvine, Calif.-based company will cover all further development and regulatory costs in North America, as well as manufacturing and commercialization expenses, of iganidipine and a new formulation of latanoprost. It is paying Senju an up-front fee and development and approval milestones of $8 million for each product, or $16 million total. The products could reach the market by 2011, and the deal includes royalties back to Osaka, Japan-based Senju.
"We ...